Gaois

Cóip statach de shonraí a easpórtáiltear ó IATE ó am go chéile atá sa chnuasach seo. Níor cheart glacadh leis gurb ionann i gcónaí an t-eolas a thugtar faoi iontráil anseo agus a bhfuil sa leagan reatha den iontráil ar IATE. Is féidir an leagan reatha sin a cheadú ach cliceáil ar an nasc atá ar thaobh na láimhe deise ag barr gach iontrála. Breis eolais »

9 dtoradh

  1. SCIENCE|natural and applied sciences|life sciences · SOCIAL QUESTIONS|health|medical science|epidemiology|disease vector

    #596305

    IATE #3588006
    coróinvíreas nua 2019 Tagairt Comhairle-GA
    ga
    géarshiondróm trom riospráide, coróinvíreas 2 Tagairt Togra le haghaidh Cinneadh maidir leis an gCorrlach Teagmhais a shlógadh in 2020 chun cabhair éigeandála a sholáthar do na Ballstáit agus breis treisithe a dhéanamh ar an Sásra Aontais um Chosaint Shibhialta/rescEU mar fhreagairt ar an ráig COVID-19
    ga
    Comhthéacs 'I dtaca leis an ngéarshiondróm trom riospráide, coróinvíreas 2 (SARS-CoV-2), agus i dtaca leis an ngalar a bhaineann leis (COVID-19), tuairiscíonn an Eagraíocht Dhomhanda Sláinte (EDS), agus an tuairisc sin arna bunú ar na saintréithe a bhaineann leo, gur éigeandáil sláinte poiblí arb ábhar imní 9 ar leibhéal idirnáisiúnta agus paindéim dhomhanda 10 iad, faoi seach.' Tagairt Togra le haghaidh Cinneadh maidir leis an gCorrlach Teagmhais a shlógadh in 2020 chun cabhair éigeandála a sholáthar do na Ballstáit agus breis treisithe a dhéanamh ar an Sásra Aontais um Chosaint Shibhialta/rescEU mar fhreagairt ar an ráig COVID-19
    géarshiondróm trom riospráide choróinvíreas 2 Tagairt Comhairle-GA
    ga
    coróinvíreas nua Tagairt Suíomh gréasáin na Comhairle (13.3.2020)
    ga
    Comhthéacs "Dhearbhaigh an Eagraíocht Dhomhanda Sláinte an Coróinvíreas nua (2019-nCoV) mar éigeandáil sláinte poiblí lena mbaineann ábhar imní idirnáisiúnta." Tagairt Preasráiteas ó Rialtas na hÉireann (13.3.2020)
    Virus, das COVID-19 verursacht | 2019-nCoV | SARS-CoV-2 | schweres akutes Atemwegssyndrom Coronavirus 2 | Coronavirus SARS-CoV-2 | Covid-19 | neuartiges Coronavirus
    de
    Sainmhíniú zu der gleichen Gruppe Coronaviren wie das SARS-Coronavirus IATE:389626 und das MERS-Coronavirus IATE:3549541 (ß-Coronaviren) gehörendes neuartiges Virus, das wie andere Erreger von Atemwegserkrankungen zu Krankheitszeichen wie Husten, Schnupfen, Halskratzen und Fieber führen und bei einem Teil der Patienten mit einem schwereren Verlauf einhergehen und zu Atemproblemen und Lungenentzündung führen kann Tagairt Council-DE nach Bundeszentrale für gesundheitliche Aufklärung - Infektionsschutz.de > Informationen zum neuartigen Coronavirus SARS-CoV-2 (10.3.2020)
    Nóta Man nimmt an, dass der Vorläufer des SARS-CoV-2 von Wildtieren stammt. Derzeit wird davon ausgegangen, dass sich die ersten Patienten Anfang Dezember auf einem Markt in Wuhan angesteckt haben, der am 01.01.2020 geschlossen wurde.
    COVID-19 coronavirus | Wuhan seafood market pneumonia virus | virus responsible for COVID-19 | severe acute respiratory syndrome coronavirus 2 | 2019-nCoV | novel coronavirus | COVID-19 virus | SARS-CoV-2 | 2019 novel coronavirus
    en
    Sainmhíniú virus in the coronavirus family, first reported from Wuhan City, Hubei Province, China on 31 December 2019, which does not match any other known virus, and which causes COVID-19 Tagairt COM-Terminology Coordination and COM-EN, based on:World Health Organization (WHO). 'Novel Coronavirus (2019-nCoV)' (10.2.2020)
    Nóta It was identified by the Chinese authorities on 7.1.2020
    coronavirus de Wuhan | coronavirus du syndrome respiratoire aigu sévère 2 | nouveau coronavirus (2019-nCoV) | 2019-nCoV | SARS-CoV-2 | nouveau coronavirus 2019 | SRAS-CoV-2
    fr
    Sainmhíniú nouveau coronavirus proche du virus du syndrome respiratoire aigu sévère (SRAS) et du virus du syndrome respiratoire du Moyen-Orient (MERS), qui a été découvert fin décembre dans la ville de Wuhan, province de Hubei en Chine Tagairt Vidal, Site des professionnels de santé, Coronavirus 2019-nCoV : le point sur la situation en France et dans le monde (11.2.2020)
    Nóta COVID-19 est le nom choisi en février 2020 par l'OMS pour désigner la maladie causée par ce virus. Ce terme, qui au sens strict fait référence à la maladie, est toutefois souvent utilisé pour désigner le virus.
    Severe acute respiratory syndrome-related coronavirus
    la
    SARS-CoV-2 | 2019-nCoV | Severe acute respiratory syndrome-related coronavirus
    mul
  2. SCIENCE|natural and applied sciences|life sciences|biology · SOCIAL QUESTIONS|health|illness|epidemic

    #599858

    IATE #3623523
    an t-athraitheach Omicron Tagairt Comhairle-GA, bunaithe ar na Dréacht-Chonclúidí ón gComhairle Eorpach, 16-17 Nollaig 2021
    ga
    Comhthéacs '...agus go dtugann na réamh-mheastóireachtaí le tuiscint go bhféadfadh teanndáileoga an chosaint ar an athraitheach Omicron a mhéadú, athraitheach ar díol imní é...' Tagairt ST 15253 2021 INIT - GA
    athraitheach Omicron SARS-CoV-2 Tagairt Comhairle-GA, bunaithe ar IATE:3592255 (athraitheach Sars-CoV-2)
    ga
    Variante Omikron | Omikron-Variante | COVID-19-Variante Omikron | SARS-CoV-2-Variante Omikron
    de
    Sainmhíniú SARS-CoV-2-Variante, die erstmals im November 2021 in Südafrika entdeckt wurde und von der WHO als besorgniserregende Variante eingestuft wurde Tagairt Council-DE
    Nóta nach dem 15. Buchstaben des griechischen Alphabets benannt
    Omicron variant | SARS-CoV-2 Omicron variant
    en
    Sainmhíniú COVID-19 virus variant that was first detected in South Africa and was named after the 15th letter of the Greek alphabet Tagairt COM-Terminology Coordination, based on: How Omicron, the new COVID-19 variant, got its name - The Economic Times (indiatimes.com)
    variant omicron du SARS-CoV-2 | variant omicron
    fr
    Sainmhíniú variant du SARS-CoV-2 désigné le 26 novembre 2021 comme variant préoccupant par l'Organisation mondiale de la santé Tagairt Conseil-FR, d'après: Ministère français de l'enseignement supérieur, de la recherche et de l'innovation, Variant omicron: Que sait-on à l'heure actuelle? (14.12.2021)
  3. SCIENCE|natural and applied sciences|life sciences|biology

    #598145

    IATE #3592255
    athraitheach SARS-CoV-2 Tagairt Rialachán (AE) 2021/953 maidir le creat chun deimhnithe idir-inoibritheacha COVID-19 i ndáil le vacsaíniú, tástáil agus téarnamh (Deimhniú Digiteach COVID AE) a eisiúint agus a fhíorú, agus chun go nglacfaí leo, chun an tsaorghluaiseacht a éascú le linn phaindéim COVID-19
    ga
    Comhthéacs '...go dtéann an staid eipidéimeolaíoch i mBallstát nó i réigiún laistigh de Bhallstát in olcas go tapa, go háirithe mar thoradh ar athraitheach SARS-CoV-2 is ábhar imní nó suime...' Tagairt Rialachán (AE) 2021/953 maidir le creat chun deimhnithe idir-inoibritheacha COVID-19 i ndáil le vacsaíniú, tástáil agus téarnamh (Deimhniú Digiteach COVID AE) a eisiúint agus a fhíorú, agus chun go nglacfaí leo, chun an tsaorghluaiseacht a éascú le linn phaindéim COVID-19
    athraitheach víreas COVID-19 Tagairt Comhairle-GA, bunaithe ar 'athraitheach víris' in Rialachán 2021/953 CELEX:32021R0953/GA
    ga
    athraitheach COVID-19 Tagairt Comhairle-GA
    ga
    SARS-CoV-2-Variante | COVID-19-Virusvariante | SARS-CoV-2-Virusvariante | Coronavirusvariante
    de
    Nóta XREF: SARS-CoV-2
    COVID-19 virus variant | Covid-19 variant | SARS-CoV-2 variant
    en
    Sainmhíniú virus responsible for COVID-19 presenting changes in its RNA sequence compared to the virus as discovered initially Tagairt COM-Terminology Coordination, based on: - Science Media Centre. expert reaction to the new variant of SARS-CoV-2 (4.1.2021)- Adam Forrest. 'Covid: New strain, variant or mutation? What’s the difference?' (4.1.2021). Independent Tuesday 22 December 2020 17:10
    variant du Covid-19 | variant du SARS-CoV-2 | variant | variant du virus de la COVID-19 | variant de la COVID-19
    fr
    Sainmhíniú virus responsable de la COVID-19 qui se distingue du virus d'origine par une ou plusieurs mutations Tagairt Conseil-FR d'après le site de l'Inserm, Salle de presse, "Un variant du SARS-CoV-2 inquiétant, vraiment?" (18.5.2021)
    Nóta Un variant résulte d'une mutation du virus qui intervient lors de la reproduction du virus.
  4. SOCIAL QUESTIONS|health|health policy|organisation of health care|public health

    #599169

    IATE #3599441
    deais maidir le hathraithigh SARS-CoV-2 Tagairt Faomhadh an téarma seo mar chuid de Thionscadal Lex
    ga
    SARS-CoV-2-Varianten-Dashboard
    de
    SARS-CoV-2 variants dashboard
    en
    Sainmhíniú ECDC dashboard which provides an overview of the proportion of variants of concern and variants of interest in EU/EEA Member States together with sequencing volumes Tagairt European Centre for Disease Prevention and Control > SARS-CoV-2 variants dashboard (2.6.2021)
    tableau de bord des variants du SARS-CoV-2
    fr
    Sainmhíniú tableau d'indicateurs du Centre européen de prévention et de contrôle des maladies fournissant une vue d'ensemble de la proportion de variants préoccupants et de variants à suivre dans l'UE/EEE ainsi que des volumes de séquençage Tagairt COM-FR d'après:- European Centre for Disease Prevention and Control > SARS-CoV-2 variants dashboard- recommandation (UE) 2021/961 modifiant la recommandation (UE) 2020/1475 relative à une approche coordonnée de la restriction de la libre circulation en réaction à la pandémie de COVID-19
  5. SOCIAL QUESTIONS|health|illness|infectious disease

    #596999

    IATE #3589452
    ionfhabhtú le SARS-CoV-2 Tagairt Faomhadh an téarma seo mar chuid de Thionscadal Lex
    ga
    ionfhabhtú COVID-19 Tagairt Faomhadh an téarma seo mar chuid de Thionscadal Lex
    ga
    Comhthéacs 'Leagtar amach sa chomhairle seo an córas glantacháin is gá chun tacú le scoileanna chun ionfhabhtú COVID-19 a chosc agus an glanadh breise a theastaíonn i gcásanna amhrasta COVID-19.' Tagairt 'Rialtas na hÉireann,' https://www.gov.ie/ga/foilsiuchan/slainteachas-agus-glantachan-sa-scoil-plean-freagartha-covid-19-le-haghaidh-athoscailt-shabhailte-inbhuanaithe-iar-bhunscoileanna/ [30.10.2020]
    Infektion mit SARS-CoV-2 | Covid-19-Infektion
    de
    COVID-19 infection | infection with SARS-CoV-2
    en
    Sainmhíniú infection with the COVID-19 virus (SARS-CoV-2) Tagairt COM-Terminology Coordination, based on: WHO. 'Laboratory testing for coronavirus disease (COVID-19) in suspected human cases' (9.4.2020). Interim guidance, 19 March 2020.
    infection par le SARS-CoV-2 | infection par la COVID-19
    fr
    Nóta Voir SARS-CoV-2
  6. SOCIAL QUESTIONS|health|pharmaceutical industry|pharmaceutical product|vaccine

    #599236

    IATE #3599599
    spícephróitéin réamhleá SARS-CoV-2 chobhsaithe Tagairt Faomhadh an téarma seo mar chuid de Thionscadal Lex
    ga
    SARS-CoV2 prefusion Spike delta TM | stabilised SARS-CoV-2 pre-fusion S protein
    en
    Sainmhíniú pre-fusion spike protein of SARS-CoV-2 as it has been stabilised in order to be used in a vaccine Tagairt COM-Terminology Coordination, based on:- Paul A Goepfert, Bo Fu, Anne-Laure Chabanon, Matthew I Bonaparte, Matthew G Davis, Brandon J Essink, et al. 'Safety and immunogenicity of SARS-CoV-2 recombinant protein vaccine formulations in healthy adults: interim results of a randomised, placebo-controlled, phase 1–2, dose-ranging study' (18.6.2021). Lancet Infect Dis. April 19, 2021- 'Supplementary appendix 2' (18.6.2021). Supplement to: Goepfert PA, Fu B, Chabanon A-L, et al. Safety and immunogenicity of SARS-CoV-2 recombinant protein vaccine formulations in healthy adults: interim results of a randomised, placebo-controlled, phase 1–2, dose-ranging study. Lancet Infect Dis 2021; published online April 19. https://doi.org/10.1016/S1473-3099(21)00147-X
    CoV2 preS dTM
    mul
  7. SOCIAL QUESTIONS|health|pharmaceutical industry|pharmaceutical product|vaccine

    #599235

    IATE #3599598
    vacsaín nanacháithníní spícephróitéine athchuingreach SARS-CoV-2 Tagairt Faomhadh an téarma seo mar chuid de Thionscadal Lex
    ga
    SARS-CoV-2 recombinant spike protein nanoparticle vaccine
    en
    Sainmhíniú recombinant severe acute respiratory syndrome coronavirus 2 (rSARS-CoV-2) nanoparticle vaccine composed of trimeric full-length SARS-CoV-2 spike glycoproteins and Matrix-M1 adjuvant Tagairt Cheryl Keech, M.D., Ph.D., Gary Albert, M.S., Iksung Cho, M.S., Andreana Robertson, M.S., Patricia Reed, B.S., Susan Neal, Joyce S. Plested, Ph.D., Mingzhu Zhu, Ph.D., Shane Cloney-Clark, B.S., Haixia Zhou, Ph.D., Gale Smith, Ph.D., Nita Patel, M.S., Matthew B. Frieman, Ph.D., Robert E. Haupt, M.S., James Logue, B.A., Marisa McGrath, B.A., Stuart Weston, Ph.D., Pedro A. Piedra, M.D., Chinar Desai, B.S., Kathleen Callahan, M.S., Maggie Lewis, M.S., Patricia Price-Abbott, M.S., Neil Formica, M.B., B.S., Vivek Shinde, M.D., Louis Fries, M.D., Jason D. Lickliter, M.B., B.S., Ph.D., Paul Griffin, M.D., Bethanie Wilkinson, Ph.D., and Gregory M. Glenn, M.D., 'Phase 1–2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine' (18.6.2021), New England Journal of Medicine 2020; 383:2320-2332
    NVX-CoV2373
    mul
  8. SOCIAL QUESTIONS|health|medical science|epidemiology

    #598755

    IATE #3598829
    athraitheach ar díol spéise é Tagairt Faofa ag an gCoiste Téarmaíochta, www.tearma.ieFaomhadh an téarma seo mar chuid de Thionscadal Lex
    ga
    Variante unter Beobachtung
    de
    variant of interest | VOI | SARS-CoV-2 variant of interest
    en
    Sainmhíniú SARS-CoV-2 isolate which:- is phenotypically changed compared to a reference isolate or has a genome with mutations that lead to amino acid changes associated with established or suspected phenotypic implications; AND- has been identified to cause community transmission/multiple COVID-19 cases/clusters, or has been detected in multiple countries; OR- is otherwise assessed to be a variant of interest by WHO in consultation with the WHO SARS-CoV-2 Virus Evolution Working Group Tagairt COM-CS based on: WHO. COVID-19 Weekly Epidemiological Update, 25 February 2021, Special edition: Proposed working definitions of SARS-CoV-2 Variants of Interest and Variants of Concern (3.5.2021)
    variant d'intérêt | variant à suivre | VOI
    fr
    Sainmhíniú variant du SARS-CoV-2:- qui présente des modifications génétiques dont on sait qu’elles affectent ou dont on prévoit qu’elles affecteront les caractéristiques du virus telles que la transmissibilité, la gravité de la maladie, l’échappement immunitaire, la capacité d’échapper au diagnostic ou au traitement; et- qui cause une transmission communautaire importante ou plusieurs foyers de COVID-19, dans plusieurs pays; ou- qui est considéré comme un variant à suivre par l'OMS, en consultation avec le groupe de travail de l’OMS sur l’évolution du virus Tagairt COM-FR d'après le site de l'OMS > Accueil > Activités> Suivi des variants du SARS-CoV-2 (11.8.2021)
  9. SOCIAL QUESTIONS|health|medical science|epidemiology

    #598236

    IATE #3592561
    athraitheach ar díol imní é Tagairt Dréacht-Chonclúidí ón gComhairle Eorpach, 16-17 Nollaig 2021
    ga
    besorgniserregende SARS-CoV-2-Virusvariante | besorgniserregende Variante
    de
    Sainmhíniú Virusvariante, die sich in ihren Erregereigenschaften wie beispielsweise der Übertragbarkeit, der Virulenz, oder der Suszeptibilität gegenüber der Immunantwort von genesenen oder geimpften Personen relevant von den herkömmlichen Virusvarianten unterscheidet Tagairt Robert Koch Institut: Startseite > Infektionskrankheiten A-Z > Coronavirus SARS-CoV-2 > Übersicht und Empfehlungen zu besorgniserregenden SARS-CoV-2-Virusvarianten (VOC) (4.5.2021)
    variant of high concern | VOC | variants of high concern | variants of concern | immune escape variant of concern | variant of concern | immune escape variants of concern | SARS-CoV-2 variant of concern
    en
    Sainmhíniú SARS-CoV-2 variant which has mutations or combinations of mutations which may provide the virus with a selective advantage, such as increased transmissibility or the ability to evade the host immune response and thus lead to deteriorating epidemiological situations in the areas where they have recently become established Tagairt COM-Terminology Coordination, based on: ECDC. 'Risk related to the spread of new SARS-CoV-2 variants of concern in the EU/EEA – first update' (27.1.2021)
    variant préoccupant
    fr